Review Article

In Vivo Tracking of Cell Therapies for Cardiac Diseases with Nuclear Medicine

Table 2

Preclinical studies that used indirect radiopharmaceutical tracking for cell therapies in models of myocardial infarction.

Study referenceRadiopharmaceutical used for cell trackingTime window of cell injection after lesion inductionAnimalsCell typeRoute(s)Number of cells injectedTime points of analysis after cell therapy

Gyöngyösi et al., 2008 [57]18F-FHBG16 daysPigsPorcine BM-MSCsIntravenous1.1 × 10530 hours
7, 16, and 23 days
Terrovitis et al., 2008 [58]124I
Tc
ImmediatelyWistar Kyoto ratsRat CDCsIntravenous2 × 1061 hour
Lee et al., 2011 [59]18F-FHBG30 minutesDogsCanine iPSCs Intramyocardial1 × 1068 hours
Liu et al., 2012 [60]18F-FHBGImmediatelySCID Beige miceHuman CDCsIntramyocardial1 × 1061, 7, 14, 21, and 28 days
Templin et al., 2012 [62]123INot specifiedPigsHuman iPSCsIntramyocardial1 × 1081 and 5 days and 12-15 weeks
Lan et al., 2012 [61]18F-FHBGImmediatelySCID Beige miceHuman CDCsIntramyocardial1 × 1061, 7, 14, 21, and 28 days
Yan et al., 2013 [63]18F-FHBG10 minutesNude miceMurine BM-MSCsIntramyocardial1 × 106Same day, 3 and 7 days
Pei et al., 2014 [64]18F-FHBGImmediatelySprague-Dawley ratsRat BM-MSCsIntramyocardial5 × 1062, 3, and 7 days
Lee et al., 2015 [65]Tc7 daysDogsCanine ADSCsIntramyocardial1 × 1072 hours and 1, 2, 5, 7, 9, and 12 days

123I: iodine-123; 124I: iodine-124; 18F: fluorine-18; Tc: technetium-99m; ADSCs: adipose tissue-derived stem cells; BM-MSCs: bone marrow mesenchymal stem cells; CDCs: cardiac-derived stem/progenitor cells; FHBG: 9-[4-fluoro-3-(hydroxymethyl)butyl]guanine derivatives; iPSCs: induced pluripotent stem cells; SCID: severe combined immunodeficiency.